Phibro Animal Health Reports Q1 2027 Growth Amid Poultry Market Pressures
Phibro Animal Health (PAHC) reported first-quarter fiscal year 2027 net sales of $386.8 million, representing a 6% increase year-over-year. While the company saw significant growth in its Mineral Nutrition and Performance Products segments due to higher commodity prices, it faced headwinds from the poultry market. Increased U.S. chicken supply has squeezed producer margins, leading customers to temporarily reduce purchases of nutritional specialties and vaccines. Management is currently focused on a strategic pivot toward higher-margin specialty markets, including plant nutrition, dairy, and pet food. Additionally, leadership is prioritizing the reduction of excess inventory to unlock working capital and improve cash flow. Despite short-term poultry market softness, Phibro maintained its full-year net sales guidance of $1.5 billion to $1.6 billion.
Tickers: $PAHC
Topics: earnings report market trends revenue growth segment performance